TMEM37 and urinary bladder carcinoma: All compounds were tested against a panel of human bladder cancer cell lines—the increasingly metastatic TSU-Pr1 series (TSU-Pr1, TSU-Pr1-B1, and TSU-Pr1-B2), and the superficial bladder cancer (5637) cell lines.